Patents by Inventor Sarah C. Bodary

Sarah C. Bodary has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090054300
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases
    Type: Application
    Filed: March 2, 2004
    Publication date: February 26, 2009
    Inventors: Alexander Abbas, Sarah C. Bodary, Hilary Clark, Jill R. Schoenfeld, P. Mickey Williams, William I. Wood, Thomas D. Wu
  • Publication number: 20080175842
    Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.
    Type: Application
    Filed: May 25, 2007
    Publication date: July 24, 2008
    Applicant: Genentech, Inc.
    Inventors: Sarah C. Bodary, Karen L. Fisher
  • Patent number: 7226596
    Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.
    Type: Grant
    Filed: August 22, 2002
    Date of Patent: June 5, 2007
    Assignee: Genentech, Inc.
    Inventors: Sarah C. Bodary, Karen L. Fisher
  • Publication number: 20040258678
    Abstract: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: February 21, 2003
    Publication date: December 23, 2004
    Applicant: Genentech, Inc.
    Inventors: Sarah C. Bodary, Hilary Clark, Brisdell Hunte, Janet K. Jackman, Jill R. Schoenfeld, P. Mickey Williams, William I. Wood, Thomas D. Wu
  • Publication number: 20040121370
    Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.
    Type: Application
    Filed: September 9, 2003
    Publication date: June 24, 2004
    Applicant: Genentech, Inc.
    Inventors: Daryl T. Baldwin, Sarah C. Bodary, Andrew C. Chan, Hilary Clark, Janet K. Jackman, William I. Wood
  • Patent number: 6602878
    Abstract: Acylquanidines of the formula wherein the substituents are defined as in the specification which are antagonists of the vitronectin receptor and inhibitors of cell adhesion and bone resorption mediated by the osteoclasts.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: August 5, 2003
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Jean-Marie Ruxer, Sarah C. Bodary
  • Patent number: 6586442
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and it prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 26, 2002
    Date of Patent: July 1, 2003
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Publication number: 20030113764
    Abstract: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of an ADAM8 gene that is amplified in the genome of tumor cells. Such gene amplification is associated with the overexpression of the gene product as compared to normal cells of the same tissue type and contributes to tumorigenesis. Accordingly, the ADAM8 protein encoded by the amplified gene is a useful target for the diagnosis and/or treatment (including prevention) of certain cancers, and acts as a predictor of the prognosis of tumor treatment.
    Type: Application
    Filed: August 22, 2002
    Publication date: June 19, 2003
    Applicant: Genentech, Inc.
    Inventors: Sarah C. Bodary, Karen L. Fisher
  • Patent number: 6500815
    Abstract: The invention concerns compounds of formula (I) wherein: X, Y, R1, R2, Z, G are as defined in the description, the methods for preparing them and the intermediates in said method, their use as medicine and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: December 17, 2001
    Date of Patent: December 31, 2002
    Assignees: Aventis Pharma S.A., Genentech
    Inventors: Denis Carniato, Thomas R. Gadek, Jochen Knolle, Jean-Francois Gourvest, Anurschirwan Peyman, Sarah C. Bodary
  • Patent number: 6458801
    Abstract: A compound of the formula wherein the substituents are as defined in the specification and its pharmaceutically acceptable salts and its prodrug useful for treating osteoporosis.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Thomas R. Gadek, Jean-Francois Gourvest, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary
  • Patent number: 6459001
    Abstract: The subject of the invention is the products of formula (I): in which R1, R2, R3, R4, R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: October 1, 2002
    Assignees: Aventis Pharma S.A., Genetech
    Inventors: Serge Bernard, Denis Carniato, Jean-Francois Gourvest, Jean-Georges Teutsch, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Sarah C. Bodary, Thomas R. Gadek, Robert S. McDowell, Robert M. Pitti
  • Patent number: 6391904
    Abstract: A compound of the formula where the substituents are defined in the specification and its pharmaceutically acceptable salts and prodrugs thereof useful as antagonists of vitronectin receptors.
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: May 21, 2002
    Assignees: Aventis Pharma S.A., Genentech, Inc.
    Inventors: Denis Carniato, Jean-Francois Gourvest, Jean-Marie Ruxer, Jochen Knolle, Anurschirwan Peyman, Sarah C. Bodary, Thomas R. Gadek
  • Patent number: 6369204
    Abstract: The invention relates to monoclonal antibodies to the &agr;v&bgr;3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on &agr;v&bgr;3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: April 9, 2002
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Patent number: 6359126
    Abstract: The invention relates to monoclonal antibodies to the &agr;v&bgr;3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies recognize unique epitopes on &agr;v&bgr;3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: June 13, 1997
    Date of Patent: March 19, 2002
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Patent number: 6221907
    Abstract: The subject of the invention is the products of formula (I): in which R1, R2, R3, R4, R5 and G are as defined in the description, the dotted lines represent an optional second bond, as well as the addition salts with acids and bases and the esters, their preparation process and the intermediates of this process, their use as medicines and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: February 2, 1999
    Date of Patent: April 24, 2001
    Assignee: Hoechst Marion Roussel
    Inventors: Serge Bernard, Denis Carniato, Jean-Francois Gourvest, Jean-Georges Teutsch, Jochen Knolle, Hans-Ulrich Stilz, Volkmar Wehner, Sarah C. Bodary, Thomas R. Gadek, Robert S. McDowell, Robert M. Pitti
  • Patent number: 5837486
    Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: November 17, 1998
    Assignee: Genentech, Inc.
    Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier
  • Patent number: 5726290
    Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: March 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier
  • Patent number: 5726037
    Abstract: Methods are provided for the preparation in recombinant host cells of biologically active soluble variants of discretely encoded, heteromultimer polypeptide receptors. Such variants are synthesized by the secretion from recombinant transformants of transmembrane-modified heteromultimer receptors. Preferred receptors are extracellular matrix, cell surface, or plasma protein-binding receptors such as GPIIb-IIIa.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: March 10, 1998
    Assignee: Genentech, Inc.
    Inventors: Sarah C. Bodary, Cornelia M. Gorman, John W. McLean, Mary A. Napier
  • Patent number: 5652110
    Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: July 29, 1997
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai
  • Patent number: 5652109
    Abstract: The invention relates to monoclonal antibodies to the .alpha.v.beta.3 integrin receptor known to be expressed in large amounts on the surface of osteoclasts and accordingly, associated with bone resorption. The disclosed monoclonal antibodies are believed to recognize unique epitopes on .alpha.v.beta.3 and are useful in the treatment of conditions associated with excessive bone resorption and/or in the inhibition of tumor cell growth.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: July 29, 1997
    Assignee: Genentech, Inc.
    Inventors: Kyung Jin Kim, Michael A. Horton, Sarah C. Bodary, Anan Chuntharapai